Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes.

Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS.

Mol Psychiatry. 2006 Dec;11(12):1116-25. Epub 2006 Sep 12.

PMID:
16969367
2.

The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials.

Chuang DM.

Ann N Y Acad Sci. 2005 Aug;1053:195-204. Review.

PMID:
16179524
3.

[Neuroprotective actions of lithium].

Hashimoto R, Fujimaki K, Jeong MR, Senatorov VV, Christ L, Leeds P, Chuang DM, Takeda M.

Seishin Shinkeigaku Zasshi. 2003;105(1):81-6. Review. Japanese.

PMID:
12701214
4.
5.

Experimental studies and controlled clinical testing of valproate and vigabatrin.

Gram L.

Acta Neurol Scand. 1988 Oct;78(4):241-70. Review.

PMID:
3146860
6.

Glia as a turning point in the therapeutic strategy of Parkinson's disease.

L' Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B.

CNS Neurol Disord Drug Targets. 2010 Jul;9(3):349-72. Review.

PMID:
20438439
7.
8.

Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases.

Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire A, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW.

Prog Brain Res. 2004;146:168-83. Review.

PMID:
14699964
9.

[Possible relation of BDNF and GDNF to neuropsychiatric disorders].

Hibi Y, Nitta A, Nabeshima T, Yamada K.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2009 Apr;29(2):85-9. Review. Japanese.

PMID:
19562947
10.
11.

Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain.

Bustos G, Abarca J, Campusano J, Bustos V, Noriega V, Aliaga E.

Brain Res Brain Res Rev. 2004 Dec;47(1-3):126-44. Review.

PMID:
15572168
13.

Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.

Marchetti B, Serra PA, L'Episcopo F, Tirolo C, Caniglia S, Testa N, Cioni S, Gennuso F, Rocchitta G, Desole MS, Mazzarino MC, Miele E, Morale MC.

Ann N Y Acad Sci. 2005 Dec;1057:296-318. Review.

PMID:
16399902
14.

Critical role of brain-derived neurotrophic factor in mood disorders.

Hashimoto K, Shimizu E, Iyo M.

Brain Res Brain Res Rev. 2004 May;45(2):104-14. Review.

PMID:
15145621
15.

Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily.

Krieglstein K, Suter-Crazzolara C, Unsicker K.

J Neural Transm Suppl. 1995;46:209-16. Review.

PMID:
8821057
16.

Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.

Fumagalli F, Racagni G, Riva MA.

Pharmacogenomics J. 2006 Mar-Apr;6(2):95-104. Review.

PMID:
16402079
17.

Regulation of respiratory neuron development by neurotrophic and transcriptional signaling mechanisms.

Katz DM.

Respir Physiol Neurobiol. 2005 Nov 15;149(1-3):99-109. Review.

PMID:
16203214
18.

GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease.

Kramer ER, Liss B.

FEBS Lett. 2015 Dec 21;589(24 Pt A):3760-72. doi: 10.1016/j.febslet.2015.11.006. Epub 2015 Nov 7. Review.

19.

Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease.

Murer MG, Yan Q, Raisman-Vozari R.

Prog Neurobiol. 2001 Jan;63(1):71-124. Review.

PMID:
11040419
20.

Reactive astrocytes as potential manipulation targets in novel cell replacement therapy of Parkinson's disease.

Chen LW, Yung KL, Chan YS.

Curr Drug Targets. 2005 Nov;6(7):821-33. Review.

PMID:
16305461

Supplemental Content

Support Center